US Supreme Court Extends Stay on Mail Delivery of Abortion Pill Mifepristone
The US Supreme Court has issued an order extending a stay that temporarily preserves nationwide mail access to mifepristone, a widely used abortion medication. This decision halts the enforcement of a previous ruling by the US 5th Circuit Court of Appeals, which had sought to ban the mailing of the drug and require in-person pickups at health clinics. The legal challenge originated from a lawsuit filed by the state of Louisiana against the Food and Drug Administration (FDA), arguing for stricter regulations on the drug's distribution. Manufacturers Danco Laboratories and GenBioPro successfully petitioned the Supreme Court to pause the appeals court's order while they prepare for further legal proceedings. Justices Samuel Alito and Clarence Thomas dissented from the majority decision to extend the stay. Mifepristone, approved by the FDA since 2000, is utilized in the majority of abortions in the United States and for managing early miscarriages. This ruling maintains the status quo regarding telemedicine prescriptions and mail-order delivery until the Supreme Court decides whether to hear the case fully, amidst ongoing national debates and varying state-level restrictions on abortion access following the overturning of Roe v. Wade.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection